CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects

Bibliography

• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Diabetes Atlas, Fifth Edition. 2011. IDF website. Available from: http://www.idf.org
   Google Scholar
• Gaede P, Lund-Andersen H, Parving H-L, Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cytochrome P450 mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol 2011;7:1065-82
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Shehab N, Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12
   PubMed Web of Science ®Google Scholar
• Preissner S, Kroll K, Dunkel M, SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010;38(Database issue):D237-43
   Google Scholar
• Human Cytochrome P450 Allele Nomenclature Committee. Available from: http://www.imm.ki.se/CYPalleles
   Google Scholar
• Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009;5:225-41
   PubMed Web of Science ®Google Scholar
• DiStefano J, Watanabe RM. Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals (Basel) 2010;3:2610-46
   PubMedGoogle Scholar
• Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011;12:1161-91
   PubMed Web of Science ®Google Scholar
• Sun H, Scott DO. Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chem Biol Interact 2011;194:159-67
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 2012;33:312-22
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96
   Google Scholar
• Bennett W L, Maruthur NM, Singh S, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;155:67-78
   PubMedGoogle Scholar
• Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012;46:590-8
   PubMed Web of Science ®Google Scholar
• McGraw J, Waller M. Cytochrome P450 variations in different ethnic populations. Exp Opin Drug Metab Toxicol 2012;8:371-82
   PubMed Web of Science ®Google Scholar
• Xu H, Murray M, McLachlan AJ. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab 2009;10:643-58
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Patzer O, Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycaemia. Eur J Clin Pharmacol 2011;67:471-6
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29-40
   PubMed Web of Science ®Google Scholar
• Sehra D, Sehra S, Sehra TS. Sulfonylureas: do we need to introspect safety again? Expert Opin Drug Saf 2011;10:851-61
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Zoungas S, Patel A, Chalmers J, ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Lang V, Youssef N, Light PE. The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes. Curr Diab Rep 2011;11:543-51
   PubMed Web of Science ®Google Scholar
• Abdelmoneim AS, Hasenbank SE, Seubert JM, Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012;14:130-8
   PubMed Web of Science ®Google Scholar
• Müller G, Hartz D, Pünter J, Differential interaction of glimepiride and glibenclamide with the ß-cell-sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994;1191:267-77
   PubMed Web of Science ®Google Scholar
• Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 1996;28:464-8
   PubMed Web of Science ®Google Scholar
• Tirkkonen T, Heikkilä P, Huupponen R, Potential CYP29-mediated drug-drug interactions in hospitalized type 2 diabetic patients treated with the sulfonylureas glibenclamide, glimepiride or glipizide. J Intern Med 2010;268:359-66
   PubMed Web of Science ®Google Scholar
• Schelleman H, Bilker WB, Brensinger CM, Anti-infectives and the risk of severe hypoglycemia in glipizide or glyburide. Clin Pharmacol Ther 2010;88:214-22
   PubMed Web of Science ®Google Scholar
• Xu H, Williams WS, Murray M, Effect of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclzide. Brit J Pharmacol 2008;153:1579-86
   PubMed Web of Science ®Google Scholar
• Kihara Y, Otsuki M. Interaction of gliclazide and rifampicin. Diabetes Care 2000;23:1204-5
   PubMedGoogle Scholar
• Zhou L, Naraharisetti SB, Liu L, Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010;31:228-42
   PubMed Web of Science ®Google Scholar
• Rydberg T, Jönsson A, Roder M, Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-30
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Bauer S, Meineke I, Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002;12:101-9
   PubMedGoogle Scholar
• Kirchheiner J, Brockmöller J, Meineke I, Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002;71:286-96
   PubMed Web of Science ®Google Scholar
• Niemi M, Cascorbi I, Timm Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-32
   PubMed Web of Science ®Google Scholar
• Wang R, Chen K, Wen S.Y, Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther 2005;78:9092
   Google Scholar
• Suzuki K, Yanagawa T, Shibasaki T, Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006;72:148-54
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Trienekens PH, Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008;83:288-92
   PubMed Web of Science ®Google Scholar
• Surendiran A, Pradhan SC, Agrawal A, Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011;67:797-801
   PubMed Web of Science ®Google Scholar
• Elliot DJ, Suharjono Lewis BC, Identification of the human cytochromes P450 catalysing the ratelimiting pathways of gliclazide elimination. Br J Clin Pharmacol 2007;64:450-7
   PubMed Web of Science ®Google Scholar
• Shao H, Ren XM, Liu NF, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther 2010;35:351-60
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly N, Burch L, Loss of function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS Study. Clin Pharmacol Ther 2010;87:52-6
   Web of Science ®Google Scholar
• Zhang Y, Si D, Chen X, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 2007;64:67-74
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Roots I, Goldammer M, Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokin 2005;44:1209-25
   PubMed Web of Science ®Google Scholar
• Tan B, Zhang YF, Chen XY, The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol 2010;66:145-51
   PubMedGoogle Scholar
• Holstein A, Egberts E-H. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-14
   PubMed Web of Science ®Google Scholar
• Holstein A, Patzer O, Machalke K, Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010. A German longitudinal population-based study. Diabetes Care 2012;35:972-5
   PubMed Web of Science ®Google Scholar
• Holstein A, Hammer C, Hahn M, Severe sulphonylurea-induced hypoglycaemia - a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010;9:675-81
   PubMed Web of Science ®Google Scholar
• Greco D, Oisciotta M, Gambina F, Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 2010;118:215-19
   PubMed Web of Science ®Google Scholar
• Schejter YD, Turvall E, Ackerman Z. Characteristics of patients with sulphonurea-induced hypoglycemia. J Am Med Dir Assoc 2012;13:234-8
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Ptak M, Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005;59:103-6
   Web of Science ®Google Scholar
• Ragia G, Petridis I, Tavridou A, Presence of CYP2C9*3 allele increases risk for hypoglycaemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10:1781-7
   PubMed Web of Science ®Google Scholar
• Gökalp O, Gunes A, Cam H, Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol 2011;67:1223-9
   PubMedGoogle Scholar
• Kristiansen SB, Løfgren B, Nielsen JM, Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia 2011;54:451-8
   PubMed Web of Science ®Google Scholar
• Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:744-55
   Web of Science ®Google Scholar
• NAVIGATOR Study Group. Holman RR, Haffner SM, Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-77
   PubMed Web of Science ®Google Scholar
• Schramm TK, Gislason GH, Vaag A, Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-8
   PubMed Web of Science ®Google Scholar
• Novonorm prescribing information. Novo Nordisk Inc.;2012
   Google Scholar
• Starlix prescribing information. Novartis;2012
   Google Scholar
• Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol 2008;4:529-44
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108
   PubMed Web of Science ®Google Scholar
• Niemi M, Leathart JB, Neuvonen PJ, Polymorphism in CYP2C8 is associated with reduced plasma concentration of repaglinide. Clin Pharmacol Ther 2003;74:380-7
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Müller G, Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in healthy volunteers. Clin Pharmacokinet 2004;43:267-78
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 2010;107:775-81
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niemi M, Neuvonen M, Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
   PubMed Web of Science ®Google Scholar
• Niemi M, Backmann JT, Neuvonen M, Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially harzadous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51
   PubMed Web of Science ®Google Scholar
• . Honkalammi J, Niemi M, Neuvonen PJ, Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther 2012; doi; 10.1038/clpt.2011.313; [Epub ahead of print]
   Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, et al. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011;39:1977-86
   PubMed Web of Science ®Google Scholar
• EMEA/11700/03, 21 May 2003. Available from: http://www.emea.eu.int
   Google Scholar
• Kajosaari LI, Jaakkola T, Neuvonen PJ, Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006;62:217-23
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Backman JT, Neuvonen M, Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004;58:390-6
   PubMed Web of Science ®Google Scholar
• Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003;43:649-60
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. J Clin Pharmacol 2001;70:58-65
   Web of Science ®Google Scholar
• 76. Busk Bidstrup T, Damkier P, Kristensen Olsen A, The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol 2006;61:49-57
   PubMed Web of Science ®Google Scholar
• Niemi M, Kajosaari LI, Neuvonen M, The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004;57:441-7
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Juntti-Patinen L, Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005;60:208-17
   PubMed Web of Science ®Google Scholar
• Takanohashi T, Koizumi T, Mihara R, Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. Drug Metab Pharmacokinet 2007;22:409-18
   PubMed Web of Science ®Google Scholar
• Hirshberg Y, Karara AH, Pietri AO, Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23:349-53
   PubMed Web of Science ®Google Scholar
• Anderson D, Shelley S, Crick N, A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. Int J Clin Pharmacol Ther 2002;42:457-64
   Google Scholar
• Anderson D, Shelley S, Crick N, No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol 2002;42:1358-65
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Laitila J, Neuvonen PJ, Pioglitazone is metabolized by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44-51
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Fritsche L, The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74
   PubMed Web of Science ®Google Scholar
• Cox PJ, Ryan DA, Hollis FJ, Absorption, disposition, metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer in humans. Drug Metab Dispos 2000;28:772-80
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen M, Neuvonen PJ, No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008;65:78-86
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Thomas S, Bauer S, Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006;80:657-67
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
   PubMed Web of Science ®Google Scholar
• Zhou K, Burch L, Vella S CYP2C8 variants reduce the therapeutic response to thiazolidinediones – a godarts study. Diabetologia 2010;(53 Suppl 1):S133
   Google Scholar
• Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831-6
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46:1-12
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004;76:239-49
   PubMed Web of Science ®Google Scholar
• Park JY, Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. B J Clin Pharmacol 2004;58:397-402
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Kosmiski LA, Bourne DW, Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 2012; doi: 10.1111/j.1365-2125.2012.04343.x; [Epub ahead of print]
   Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61:70-8
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA, Kang MH, Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75:157-62
   PubMed Web of Science ®Google Scholar
• Kortboyer JM, Eckland D. Pioglitazone has low potential for drug interactions. Diabetologia 1999;42(Suppl 1):A228
   Google Scholar
• Komoroski B, Vachharajani N, Boulton D, Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Paschos P, Paletas K, Dipeptidyl peptidase-4 inhibitors for treatment of type diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ. 2012;344:e1369- doi: 10.1136/bmj.e1369
   Google Scholar
• Barzilai N, Guo H, Mahoney EM, Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind,placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
   PubMed Web of Science ®Google Scholar
• Schwarz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipepdidyl pepdidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipepdidylpepdidase-4 inhibitors Diabetes Obes Metab. 2010;12:648-58
   Google Scholar
• Monami M, Dicembrini I, Martelli D, Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27S3:57-64
   Google Scholar
• Burant CF, Viswanathan P, Marcinak J, TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1403-11
   PubMed Web of Science ®Google Scholar
• Friedrich C, Ring A, Brand T, Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healty volunteers. Eur J Drug Metab Pharmacokinet 2011;36:17-24
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Chang M, Hasegawa M, Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357-65
   PubMed Web of Science ®Google Scholar
• Appel S, Rufenacht T, Kalafsky G, Lack of interaction between fluvastatin and oral hypoglycaemic agents in healthy subjects and in patients with non-insulindependent diabetes mellitus. Am J Cardiol 1995;76:29A-32A
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Niemi M, Fredrikson H, Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007;63:732-40
   PubMed Web of Science ®Google Scholar
• Semple CG, Omile C, Buchanan KD, Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol 1986;22:187-90
   PubMed Web of Science ®Google Scholar
• Roberge RJ, Kaplan R, Frank R, Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160-3
   PubMed Web of Science ®Google Scholar
• Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med 1987;107:261-2
   PubMed Web of Science ®Google Scholar
• Kubacka RT, Antal EJ, Juhl RP. The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1987;23:743-51
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Effect of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;69:194-200
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69:400-6
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivisto KT, Backman JT, Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000;50:591-5
   PubMed Web of Science ®Google Scholar